Bank of America’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-649
| Closed | -$882 | – | 5776 |
|
|
2025
Q4 | $882 | Buy |
649
+1
| +0.2% | +$1 | ﹤0.01% | 6481 |
|
|
2025
Q3 | $1.04K | Sell |
648
-25,274
| -98% | -$41.2K | ﹤0.01% | 7489 |
|
|
2025
Q2 | $36.3K | Sell |
25,922
-26,641
| -51% | -$39.9K | ﹤0.01% | 6906 |
|
|
2025
Q1 | $84.6K | Sell |
52,563
-26,204
| -33% | -$33.3K | ﹤0.01% | 6569 |
|
|
2024
Q4 | $99.2K | Buy |
78,767
+34,176
| +77% | +$53K | ﹤0.01% | 6407 |
|
|
2024
Q3 | $83.8K | Buy |
44,591
+3,020
| +7% | +$11.9K | ﹤0.01% | 6398 |
|
|
2024
Q2 | $308K | Buy |
41,571
+2,509
| +6% | +$20.7K | ﹤0.01% | 5639 |
|
|
2024
Q1 | $306K | Sell |
39,062
-10,472
| -21% | -$67.3K | ﹤0.01% | 5646 |
|
|
2023
Q4 | $252K | Buy |
49,534
+8,056
| +19% | +$41.5K | ﹤0.01% | 5943 |
|
|
2023
Q3 | $246K | Sell |
41,478
-5,610
| -12% | -$37.3K | ﹤0.01% | 5775 |
|
|
2023
Q2 | $349K | Sell |
47,088
-9,891
| -17% | -$84.2K | ﹤0.01% | 5496 |
|
|
2023
Q1 | $538K | Buy |
56,979
+36,986
| +185% | +$390K | ﹤0.01% | 5338 |
|
|
2022
Q4 | $213K | Buy |
19,993
+147
| +0.7% | +$1.49K | ﹤0.01% | 5877 |
|
|
2022
Q3 | $147K | Buy |
19,846
+68
| +0.3% | +$423 | ﹤0.01% | 6148 |
|
|
2022
Q2 | $95K | Hold |
19,778
| – | – | ﹤0.01% | 6501 |
|
|
2022
Q1 | $101K | Sell |
19,778
-4,126
| -17% | -$21.7K | ﹤0.01% | 6855 |
|
|
2021
Q4 | $144K | Buy |
23,904
+3,995
| +20% | +$30K | ﹤0.01% | 6685 |
|
|
2021
Q3 | $176K | Buy |
19,909
+19,868
| +48,459% | +$138K | ﹤0.01% | 6385 |
|
|
2021
Q2 | $0 | Sell |
41
-48
| -54% | -$377 | ﹤0.01% | 7737 |
|
|
2021
Q1 | $0 | Sell |
89
-276
| -76% | -$2.34K | ﹤0.01% | 7409 |
|
|
2020
Q4 | $3K | Buy |
365
+315
| +630% | +$3.42K | ﹤0.01% | 6886 |
|
|
2020
Q3 | $0 | Buy |
50
+18
| +56% | +$198 | ﹤0.01% | 6876 |
|
|
2020
Q2 | $0 | Hold |
32
| – | – | ﹤0.01% | 6816 |
|
|
2020
Q1 | $0 | Sell |
32
-109
| -77% | -$774 | ﹤0.01% | 6828 |
|
|
2019
Q4 | $1K | Sell |
141
-554
| -80% | -$3.82K | ﹤0.01% | 6948 |
|
|
2019
Q3 | $5K | Buy |
695
+586
| +538% | +$4.08K | ﹤0.01% | 6842 |
|
|
2019
Q2 | $1K | Buy |
109
+77
| +241% | +$774 | ﹤0.01% | 7011 |
|
|
2019
Q1 | $0 | Hold |
32
| – | – | ﹤0.01% | 7088 |
|
|
2018
Q4 | $0 | Hold |
32
| – | – | ﹤0.01% | 7089 |
|
|
2018
Q3 | $1K | Hold |
32
| – | – | ﹤0.01% | 7101 |
|
|
2018
Q2 | $1K | Hold |
32
| – | – | ﹤0.01% | 6954 |
|
|
2018
Q1 | $0 | Hold |
32
| – | – | ﹤0.01% | 7087 |
|
|
2017
Q4 | $1K | Hold |
32
| – | – | ﹤0.01% | 6904 |
|
|
2017
Q3 | $1K | Buy |
+32
| New | +$702 | ﹤0.01% | 6906 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7022 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 7093 |
|
|
2015
Q3 | – | Sell |
-58
| Closed | -$5K | – | 7192 |
|
|
2015
Q2 | $5K | Buy |
58
+56
| +2,800% | +$4.78K | ﹤0.01% | 6801 |
|
|
2015
Q1 | $0 | Buy |
+2
| New | +$238 | ﹤0.01% | 7043 |
|
|
2014
Q3 | – | Sell |
-10
| Closed | -$2K | – | 7993 |
|
|
2014
Q2 | $2K | Buy |
+10
| New | +$3.33K | ﹤0.01% | 7815 |
|
Other funds holding ATNM
VCM
GS
VFT
Bank of America's ATNM Position: Q1 2026 in Review
Bank of America sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 649 shares — an estimated $882 sold.
Bank of America first reported a position in ATNM in Q2 2014 and held it in 37 quarters. The position peaked at $538K in Q1 2023. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.
- Bank of America reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 649 Actinium Pharmaceuticals shares in Q1 2026, an estimated $882.
- Bank of America first reported a position in Actinium Pharmaceuticals in Q2 2014 and held it in 37 quarters.
- Bank of America's Actinium Pharmaceuticals position peaked at $538K in Q1 2023.
- 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.